Shares of Dolby Laboratories (NYSE:DLB – Get Free Report) have earned a consensus recommendation of “Hold” from the five brokerages that are currently covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $76.67.
Several brokerages have recently issued reports on DLB. Wall Street Zen downgraded shares of Dolby Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, August 1st. Weiss Ratings raised shares of Dolby Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, September 9th. Robert W. Baird cut their price objective on shares of Dolby Laboratories from $62.00 to $60.00 and set a “neutral” rating on the stock in a research report on Thursday. Rosenblatt Securities reduced their target price on shares of Dolby Laboratories from $85.00 to $80.00 and set a “buy” rating for the company in a research note on Monday. Finally, Zacks Research upgraded shares of Dolby Laboratories from a “strong sell” rating to a “hold” rating in a research report on Friday, November 13th.
Check Out Our Latest Research Report on DLB
Dolby Laboratories Stock Performance
Shares of Dolby Laboratories stock traded down $1.24 on Thursday, reaching $55.53. 438,311 shares of the company were exchanged, compared to its average volume of 848,875. The firm has a market cap of $5.20 billion, a price-to-earnings ratio of 20.58 and a beta of 0.79. Dolby Laboratories has a 1-year low of $48.26 and a 1-year high of $69.95. The company’s 50-day moving average is $60.80 and its two-hundred day moving average is $59.37.
Dolby Laboratories (NYSE:DLB – Get Free Report) last released its quarterly earnings data on Tuesday, November 17th. The electronics maker reported $1.25 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.05. The business had revenue of $373.54 million during the quarter, compared to analyst estimates of $372.76 million. Dolby Laboratories had a return on equity of 11.78% and a net margin of 18.14%. The business’s revenue for the quarter was up 21.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.99 EPS. Dolby Laboratories has set its Q1 2027 guidance at 0.410-0.560 EPS and its FY 2027 guidance at 4.270-4.420 EPS. As a group, sell-side analysts forecast that Dolby Laboratories will post 3.36 earnings per share for the current year.
Dolby Laboratories Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 9th. Investors of record on Tuesday, December 1st will be given a $0.39 dividend. The ex-dividend date is Tuesday, December 1st. This represents a $1.56 annualized dividend and a yield of 2.8%. This is an increase from Dolby Laboratories’s previous quarterly dividend of $0.36. Dolby Laboratories’s payout ratio is 61.28%.
Dolby Laboratories announced that its board has approved a stock repurchase plan on Thursday, July 30th that allows the company to buy back $350 million in shares. This repurchase authorization allows the electronics maker to buy up to 7% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its shares are undervalued.
Insiders Place Their Bets
In other Dolby Laboratories news, CAO Ryan Nicholson sold 1,183 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $65.28, for a total transaction of $77,226.24. Following the completion of the transaction, the chief accounting officer owned 34,453 shares in the company, valued at approximately $2,249,091.84. The trade was a 3.32% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP John Couling sold 7,667 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $58.78, for a total transaction of $450,666.26. Following the completion of the transaction, the senior vice president owned 166,803 shares of the company’s stock, valued at $9,804,680.34. This trade represents a 4.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 16,517 shares of company stock valued at $995,963 in the last quarter. 37.93% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Dolby Laboratories
Several institutional investors have recently made changes to their positions in the company. Hsbc Holdings PLC raised its position in shares of Dolby Laboratories by 396.1% during the first quarter. Hsbc Holdings PLC now owns 31,259 shares of the electronics maker’s stock valued at $1,875,000 after buying an additional 24,958 shares during the last quarter. Pacer Advisors Inc. lifted its stake in Dolby Laboratories by 8.0% during the first quarter. Pacer Advisors Inc. now owns 516,292 shares of the electronics maker’s stock worth $31,008,000 after purchasing an additional 38,389 shares during the period. Entropy Technologies LP acquired a new stake in Dolby Laboratories during the first quarter valued at approximately $1,674,000. Wellington Management Group LLP boosted its holdings in Dolby Laboratories by 19.4% during the second quarter. Wellington Management Group LLP now owns 320,156 shares of the electronics maker’s stock valued at $16,834,000 after purchasing an additional 52,053 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in Dolby Laboratories in the 2nd quarter valued at $951,000. 58.56% of the stock is currently owned by institutional investors and hedge funds.
Latest Dolby Laboratories News
These are some of the DLB news items that stood out recently:
- Positive Sentiment: Long-term licensing strengths include advanced audio and imaging patents, which generated more than half of licensing revenue; Dolby’s Video Distribution Patent Program grew to 47 licensors. Long-term investor takeaways
- Neutral Sentiment: Zacks Research increased its earnings estimates, offering a counterpoint to concerns over the company’s forward guidance. Zacks Research raises earnings estimates
- Negative Sentiment: Analysts trimmed price targets: Robert W. Baird cut its target to $60 and kept a neutral rating, while Barrington lowered its target to $80 from $90 but maintained an outperform rating. The stock also fell below its 200-day moving average. Barrington Research target change
About Dolby Laboratories
Dolby Laboratories, Inc. develops audio and imaging technologies used in entertainment and consumer electronics. Its offerings include Dolby Atmos immersive audio, Dolby Vision high-dynamic-range imaging, and technologies for encoding, delivering and reproducing sound and video. The company licenses its technologies to manufacturers and content businesses across areas such as film, television, streaming, gaming and mobile devices. Dolby also supports cinema experiences through technologies and services including Dolby Cinema.
See Also
- Five stocks we like better than Dolby Laboratories
- Lowe’s Earnings Beat Looked Strong Until a 34-Cent Tariff Refund Changed the Math
- Grounded at 52-Week Lows: When Will Boeing Stock Take Flight?
- Apple’s Next Margin Defense Could Be Hiding in Your Wallet
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
Receive News & Ratings for Dolby Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dolby Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
